Which GDMT statement for heart failure with reduced ejection fraction is true?

• A. It has no impact on survival.
• B. It is only recommended for diabetics.
• C. It is optional and not evidence-based.
• D. It improves survival and reduces hospitalizations when optimized.

Answer: (D)

Guideline-directed medical therapy for heart failure with reduced ejection fraction improves both survival and the chance of staying out of the hospital when it is started and titrated to the doses proven in trials. The core idea is that the right combination of medications—RAAS blockade with ACE inhibitors, ARBs, or ARNIs; beta-blockers; mineralocorticoid receptor antagonists; and SGLT2 inhibitors—each contributes to lower risk of death and fewer HF hospitalizations. Optimizing therapy means selecting the appropriate classes for the patient and increasing the doses toward those used in landmark studies, while regularly monitoring kidney function, potassium, blood pressure, and tolerability.

Diuretics and other symptomatic treatments help with fluid overload, but they are not the ones shown to improve long-term survival, which is why they don’t carry the same mortality and hospitalization benefits as GDMT. The statements that GDMT has no impact on survival, or that it’s only for diabetics, or that it’s optional and not evidence-based, don’t fit the evidence. When GDMT is optimized, survival improves and hospitalizations decrease.